Drug intelligence / Profile preview

AP302

Development stage: Preclinical
Lead developer: Alebund Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AP302 is a preclinical-stage therapeutic candidate developed by Alebund Pharmaceuticals, specifically designed to target Mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is a crucial enzyme in the lectin pathway of the complement system, which plays a significant role in the inflammatory response and tissue injury associated with various renal diseases. By inhibiting MASP-2, AP302 is intended to treat IgA Nephropathy (IgAN) and other forms of chronic kidney disease (CKD) by preventing the overactivation of the complement cascade, thereby reducing glomerular inflammation and preserving renal function.

Targets

CFB (Complement Factor B)MASP2 (Mannan-binding lectin-associated serine protease 2)

Beyond the preview

Go deeper on AP302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP302.

Explore the full profile